These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36647072)

  • 1. Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain.
    Isla D; Lopez-Brea M; Espinosa M; Arrabal N; Pérez-Parente D; Carcedo D; Bernabé-Caro R
    Cost Eff Resour Alloc; 2023 Jan; 21(1):6. PubMed ID: 36647072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
    Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
    Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Analysis of Atezolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer With Different PD-L1 Expression Status.
    Liu G; Kang S; Wang X; Shang F
    Front Oncol; 2021; 11():669195. PubMed ID: 33987103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1.
    Escudero-Vilaplana V; Collado-Borrell R; De Castro J; Insa A; Martínez A; Fernández E; Sullivan I; Flores A; Arrabal N; Carcedo D; Manzaneque A
    J Med Econ; 2023; 26(1):445-453. PubMed ID: 36883193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness evaluation based on two models of first-line atezolizumab monotherapy and chemotherapy for advanced non-small cell lung cancer with high-PDL1 expression.
    Zhang C; Liu Y; Tan J; Tian P; Li W
    Front Oncol; 2023; 13():1093469. PubMed ID: 36998459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.
    Liu Q; Zhou Z; Luo X; Yi L; Peng L; Wan X; Tan C; Zeng X
    Front Pharmacol; 2021; 12():788569. PubMed ID: 34992538
    [No Abstract]   [Full Text] [Related]  

  • 7. Atezolizumab compared to chemotherapy for first-line treatment in non-small cell lung cancer with high PD-L1 expression: a cost-effectiveness analysis from US and Chinese perspectives.
    Cheng S; Pei R; Li J; Li B; Tang L; Yin T; Liu S
    Ann Transl Med; 2021 Sep; 9(18):1481. PubMed ID: 34734033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Predictive Value of PD-L1 Expression Level in Evaluating the Cost-Effectiveness of Atezolizumab/Pembrolizumab.
    Lin S; Li Y; Gu D; Luo S; Huang X; Dong L; Xu X; Lin P; Weng X
    Front Oncol; 2022; 12():857452. PubMed ID: 35530317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-Line Atezolizumab for Metastatic NSCLC with High PD-L1 Expression: A United States-Based Cost-Effectiveness Analysis.
    Peng Y; Zeng X; Peng L; Liu Q; Yi L; Luo X; Li S; Wang L; Qin S; Wan X; Tan C
    Adv Ther; 2021 May; 38(5):2447-2457. PubMed ID: 33821431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness Analysis of Atezolizumab versus Platinum-Based Chemotherapy as First-Line Treatment for Patients with Unresectable Advanced Non-small Cell Lung Cancer with PD-L1 Expression Status in Japan.
    Chisaki Y; Nakano H; Minamide J; Yano Y
    Clin Drug Investig; 2023 Nov; 43(11):839-850. PubMed ID: 37891362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States.
    Huang M; Lou Y; Pellissier J; Burke T; Liu FX; Xu R; Velcheti V
    Pharmacoeconomics; 2017 Aug; 35(8):831-844. PubMed ID: 28620848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab vs cemiplimab for the treatment of advanced non-small cell lung cancer with PD-L1 expression levels of at least 50%: A network meta-analysis and cost-effectiveness analysis.
    Li Y; Liang X; Yang T; Guo S; Chen X
    Front Oncol; 2022; 12():878054. PubMed ID: 36226060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determining the optimal PD-1/PD-L1 inhibitors for the first-line treatment of non-small-cell lung cancer with high-level PD-L1 expression in China.
    Teng MM; Chen SY; Yang B; Wang Y; Han RY; An MN; Dong YL; You HS
    Cancer Med; 2021 Sep; 10(18):6344-6353. PubMed ID: 34382361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States.
    Criss SD; Mooradian MJ; Watson TR; Gainor JF; Reynolds KL; Kong CY
    JAMA Netw Open; 2019 Sep; 2(9):e1911952. PubMed ID: 31553470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States.
    Huang M; Lou Y; Pellissier J; Burke T; Liu FX; Xu R; Velcheti V
    J Med Econ; 2017 Feb; 20(2):140-150. PubMed ID: 27571538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of atezolizumab as adjuvant treatment of patients with stage II-IIIA non-small cell lung cancer, PD-L1+≥50% of tumor cells in France: A modeling study.
    Plessala I; Cawston H; Cortes J; Ajjouri R; Le Lay K; Souquet PJ; Chouaid C
    Lung Cancer; 2023 Oct; 184():107316. PubMed ID: 37562344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong.
    Loong HH; Wong CKH; Leung LKS; Dhankhar P; Insinga RP; Chandwani S; Hsu DC; Lee MYK; Huang M; Pellissier J; Rai A; Achra M; Tan SC
    Pharmacoecon Open; 2020 Jun; 4(2):235-247. PubMed ID: 31531842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of first-line immunotherapies for advanced non-small cell lung cancer.
    Yang SC; Ou HT; Su WC; Wang SY
    Cancer Med; 2023 Apr; 12(7):8838-8850. PubMed ID: 36653947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario.
    Nadal E; Bautista D; Cabezón-Gutiérrez L; Ortega AL; Torres H; Carcedo D; Ruiz de Alda L; Garcia JF; Vieitez P; Rojo F
    BMC Cancer; 2021 Jun; 21(1):689. PubMed ID: 34112097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer.
    Aziz MIA; Tan LE; Tan WHG; Toh CK; Loke LPY; Pearce F; Ng K
    J Med Econ; 2020 Sep; 23(9):952-960. PubMed ID: 32462958
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.